|
End-of-day quote
New Zealand S.E.
11/09/2026
|
5-day change | 1st Jan Change | ||
| 4.320 NZD | -1.59% |
|
-1.37% | +27.81% |
| 09-08 | Aft Pharmaceuticals Limited Partners with Mark Cuban Cost Plus Drug Company to Bring Combogesic to the U.S | CI |
| 07-31 | AFT Pharmaceuticals Limited - Shareholder/Analyst Call |
| Market Cap | 453M 263M 227M 215M 195M 366M 25.17B 367M 2.55B 982M 12.81B 990M 968M 40.47B | P/E 2027 * |
23x | P/E 2028 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 483M 281M 242M 229M 208M 390M 26.83B 392M 2.72B 1.05B 13.65B 1.05B 1.03B 43.13B | EV / Sales 2027 * |
1.59x | EV / Sales 2028 * | 1.38x |
| Free-Float |
22.37% | Yield 2027 * |
0.76% | Yield 2028 * | 0.96% |
| Markets | Quality | ||
|---|---|---|---|
New Zealand S.E.
| AFT | End-of-day quote | |
Australian S.E.
| AFP | Delayed |
Last Transcript : AFT Pharmaceuticals Limited
| 20/01/24 | Rentevrees zet Bel20 onder druk | |
| 19/01/24 | KBC uitblinker op groene beurs | |
| 19/01/24 | Brusselse beurs opent flink hoger | |
| 19/01/24 | Brussel start handelsdag vermoedelijk in het groen | |
| 18/01/24 | Hyloris gaat samenwerken met AFT Pharmaceuticals |
| 1 day | -1.59% | ||
| 1 week | -1.37% | ||
| Current month | -2.70% | ||
| 1 month | -6.09% | ||
| 3 months | +9.64% | ||
| 6 months | +23.08% | ||
| Current year | +27.81% |
| 1 week | 4.31 |  | 4.4 |
| 1 month | 4.23 | | 4.55 |
| Current year | 3.35 | | 4.85 |
| 1 year | 2.56 | | 4.85 |
| 3 years | 2.37 | | 4.85 |
| 5 years | 2.37 | | 5 |
| 10 years | 1.7 | | 5.65 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marree Atkinson
HRO | Human Resources Officer | - | 03/09/2012 |
Hartley Atkinson
CEO | Chief Executive Officer | - | 03/09/1997 |
Stuart Houliston
DFI | Director of Finance/CFO | - | 14/06/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
David Flacks
CHM | Chairman | - | 21/06/2015 |
Hartley Atkinson
BRD | Director/Board Member | - | 03/09/1997 |
Marree Atkinson
BRD | Director/Board Member | - | 03/09/2012 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 03/07/25 | Buy | Founder | 200,000 | 0.1907% | ||
| 26/06/25 | Free | Founder | 17,755 | 0.0169% | ||
| 02/12/24 | Buy | Founder | 45 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.59% | -1.37% | +66.15% | +25.95% | 267M | |
| +0.13% | -2.15% | +48.71% | +88.84% | 1,001B | |
| -0.13% | -3.30% | +49.11% | +63.63% | 642B | |
| +1.04% | +0.36% | +16.88% | +72.70% | 451B | |
| -0.38% | -3.59% | +28.24% | +35.57% | 340B | |
| -0.09% | -13.54% | +10.08% | +26.87% | 263B | |
| -0.43% | -2.48% | -2.07% | +11.48% | 247B | |
| -0.66% | -13.08% | +34.42% | +45.21% | 207B | |
| -3.44% | -7.51% | -20.08% | -59.58% | 197B | |
| -0.62% | -4.57% | +22.26% | +87.05% | 180B | |
| Average | -0.59% | -5.02% | +25.37% | +39.77% | 352.66B | |
| Weighted average by Cap. | -0.18% | -4.65% | +30.29% | +56.08% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 304M 177M 152M 144M 131M 245M 16.88B 246M 1.71B 658M 8.59B 664M 649M 27.14B | 345M 201M 173M 164M 148M 279M 19.18B 280M 1.95B 748M 9.76B 754M 738M 30.84B |
| Net income | 19.7M 11.45M 9.87M 9.35M 8.47M 15.89M 1.09B 15.97M 111M 42.68M 557M 43.02M 42.08M 1.76B | 24.81M 14.43M 12.43M 11.77M 10.67M 20.02M 1.38B 20.12M 140M 53.77M 701M 54.2M 53.01M 2.22B |
| Net Debt | 29.84M 17.35M 14.95M 14.16M 12.83M 24.07M 1.66B 24.19M 168M 64.65M 843M 65.17M 63.74M 2.67B | 24.6M 14.31M 12.33M 11.67M 10.58M 19.85M 1.37B 19.95M 139M 53.3M 695M 53.73M 52.55M 2.2B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/09/26 | NZ$4.320 | -1.59% | 5,394 |
| 10/09/26 | NZ$4.390 | -0.23% | 3,130 |
| 09/09/26 | NZ$4.400 | +2.09% | 7,156 |
| 08/09/26 | NZ$4.310 | -0.69% | 14,775 |
| 07/09/26 | NZ$4.340 | -0.69% | 8,724 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AFT Stock
Select your edition
All financial news and data tailored to specific country editions
